EMERGING ROLE OF BOTULINUM TOXIN IN THE MANAGEMENT OF VOIDING DYSFUNCTION
Abstract
Purpose:
In recent years there has been tremendous excitement over the use of botulinum neurotoxin (BTX) to treat various urethral and bladder dysfunctions. BTX is the most potent, naturally occurring toxin known to mankind. Why, then, would a urologist want to use this agent to poison the bladder or urethral sphincter?
Materials and Methods:
We reviewed the recent literature on the mechanisms underlying the effects of BTX treatment and discuss current use of this agent within the urological community, as well as provide perspective on future targets of BTX. The information was gathered from MEDLINE, abstracts from recent urological meetings and personal experience.
Results:
Injection of BTX appears to have a positive therapeutic effect in multiple urological conditions, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, and nonneurogenic conditions such as pelvic floor spasticity, refractory overactive bladder and, possibly, benign prostatic hyperplasia. Interstitial cystitis may even be potentially helped with bladder BTX injection.
Conclusions:
Botulinum toxin is a novel and promising treatment for a variety of lower urinary tract dysfunctions. The basic science behind its mechanism of action and physiology, and published clinical results are impressive. However, since application of BTX in the lower urinary tract has not been approved by the Food and Drug Administration, caution should be used until future properly designed, multicenter randomized studies are completed to assess the safety and efficacy of BTX in urological diseases.
References
- 1 : Ueber einen neuen anaeroben Bacillus and seine Beziehungen zum Botulisms. Ztsch Hyg Infekt1897; 26: 1. Google Scholar
- 2 : Botulinum toxin as a biological weapon: medical and public health management. JAMA2001; 285: 1059. Google Scholar
- 3 : Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol1996; 155: 1023. Link, Google Scholar
- 4 : Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord1998; 36: 91. Crossref, Medline, Google Scholar
- 5 : Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil1990; 71: 24. Google Scholar
- 6 : Effects of botulinum A toxin on detrusor-sphincter dys-synergia in spinal cord injury patients. J Urol1988; 139: 919. Link, Google Scholar
- 7 : Botulinum-A toxin for treating detrusor hyper-reflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol2000; 164: 692. Link, Google Scholar
- 8 : One surgeon's experience in 50 patients with botulinum toxin injection into the bladder and urethra. J Urol2002; 167: 249. abstract 981. Google Scholar
- 9 : Botulinum toxin urethral sphincter injection restores spontaneous micturition in multiple sclerosis women. J Urol2002; 167: 273. abstract 1074. Google Scholar
- 10 Smith C.P., Radziszewski P., Majewski M., Borkowski A., Boone T.B., Chancellor M.B.: Botulinum toxin A improves voiding and pain indices in patients with interstitial cystitis: a case series. Presented at annual meeting of American Urological Association, Society for Urodynamics and Female Urology, Chicago, Illinois, April 26 –May 1, 2003 Google Scholar
- 11 : Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol2003; 169: 1896. Link, Google Scholar
- 12 : Botulism. A clinical and experimental study. Rockefeller Inst Med Res Monogr1918; 8: 1. Google Scholar
- 13 :
Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin . In: Therapy With Botulinum Toxin. Edited by . New York: Marcel Dekker1994: 15. Google Scholar - 14 : Botulinum neurotoxins are zinc proteins. J Biol Chem1992; 267: 23479. Google Scholar
- 15 : Secrets of secretion revealed. Science1993; 260: 487. Google Scholar
- 16 : Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett1993; 335: 99. Google Scholar
- 17 : Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain2002; 18: S142. Google Scholar
- 18 : Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord1988; 3: 333. Google Scholar
- 19 : Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol2000; 95: 3333. Google Scholar
- 20 : Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol1999; 246: 265. Google Scholar
- 21 : Botulinum-A toxin in the treatment of detrusor hyperreflexia. Neurourol Urodyn2001; 20: 522. Google Scholar
- 22 : Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord2002; 40: 599. Google Scholar
- 23 : Transient paralysis of the bladder due to wound botulism. Eur Urol2001; 39: 610. Google Scholar
- 24 : Transient erectile dysfunction associated with intramuscular injection of botulinum toxin type A. J South Orthop Assoc2002; 11: 116. Google Scholar
- 25 : Increased residual urine volume after local injection of botulinum A toxin. Nervenarzt1995; 66: 465. Google Scholar
- 26 : Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia. Am J Gastroenterol2001; 96: 3211. Google Scholar
- 27 : Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol2003; 45: 200. Google Scholar
- 28 : Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest2002; 31: 247. Google Scholar
- 29 : Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest1997; 26: 491. Google Scholar
- 30 : Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies—therapeutic consequences. Exp Neurol1997; 147: 96. Google Scholar
- 31 : Response to botulinum toxin F in seronegative botulinum toxin A—resistant patients. Mov Disord1996; 11: 181. Google Scholar
- 32 : Response and immunoresistance to botulinum toxin injections. Neurology1995; 45: 1743. Google Scholar
- 33 : Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology2003; 60: 1186. Google Scholar
- 34 : Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve1997; 6: S146. Google Scholar
- 35 : Clean, intermittent self-catheterization in the treatment of urinary tract disease. Trans Am Assoc Genitourin Surg1971; 63: 92. Google Scholar
- 36 : Radical transurethral resection of the prostate in male paraplegics revisited: further clinical experience and urodynamic considerations for its effectiveness. J Urol1987; 137: 72. Link, Google Scholar
- 37 : Long-term followup of the North American Multicenter UroLume Trial for the treatment of external detrusor-sphincter dyssynergia. J Urol1999; 161: 1545. Link, Google Scholar
- 38 : Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial. J Urol1999; 161: 1893. Link, Google Scholar
- 39 : Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor sphincter dyssynergia application. J Urol2000; 163: 773. Link, Google Scholar
- 40 : Long-term outcome of permanent urethral stents in the treatment of detrusor-sphincter dyssynergia. Br J Urol1996; 78: 729. Google Scholar
- 41 : Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck1990; 12: 392. Crossref, Medline, Google Scholar
- 42 : Treatment of neuropathic bladder using botulinum toxin A in a 1-year old child with myelo-meningocele. Pediatr Nephrol2001; 16: 1161. Google Scholar
- 43 : Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol2002; 42: 56. Google Scholar
- 44 : Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil1998; 79: 715. Google Scholar
- 45 : Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol2001; 165: 1107. Link, Google Scholar
- 46 : Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry1997; 63: 474. Google Scholar
- 47 : Prognostic value of urodynamic testing in myelodysplastic patients. J Urol1981; 126: 205. Link, Google Scholar
- 48 : Bladder leak point pressure: the measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. J Urol1998; 159: 493. Link, Google Scholar
- 49 : Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology2003; 61: 550. Google Scholar
- 50 : Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct2002; 13: 185. Google Scholar
- 51 : The etiology of urinary retention after surgery for genuine stress incontinence. Neurourol Urodyn2001; 20: 13. Google Scholar
- 52 : Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol1992; 70: 387. Google Scholar
- 53 : Perisphincteric injection of botulinum toxin type A treatment option for patients with chronic prostatic pain?. Eur Urol2000; 38: 393. Google Scholar
- 54 : The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuro-muscular transmission. Neuroscience1982; 7: 997. Google Scholar
- 55 : Effects of botulinum toxin type A on the superior cervical ganglia in rabbits. Auton Neurosci2002; 102: 8. Google Scholar
- 56 : Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol2001; 281: H2124. Google Scholar
- 57 : Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi2001; 105: 218. Google Scholar
- 58 : Botox-induced prostatic involution. Prostate1998; 37: 44. Google Scholar
- 59 : Distant effects of local injection of botulinum toxin. Muscle Nerve1987; 10: 552. Google Scholar
- 60 :
Immunologic and other properties of therapeutic botulinum toxin serotypes . In: . Philadelphia: Lippincott Williams & Wilkins2002: 103. Google Scholar - 61 : Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol1999; 162: 3. Link, Google Scholar
- 62 : Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: A new alternative to medical and surgical procedures?. Neurourol Urodyn1999; 18: 401. Google Scholar
- 63 : Botulinum toxin-A to treat detrusor hyperreflexia in spinal cord injured patients. Neurourol Urodyn2001; 20: 521. Google Scholar
- 64 : European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. J Urol2003; 169: 373. abstract 1393. Google Scholar
- 65 : Outcome of repeat detrusor injections of botulinum A toxin (BTX-A) for severe neurogenic detrusor overactivity and incontinence. J Urol2003; 169: 373. abstract 1394. Google Scholar
- 66 : Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology2002; 59: 325. Google Scholar
- 67 : Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A— A pilot study. Neurourol Urodyn2001; 20: 410. Google Scholar
- 68 : Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn2001; 20: 412. Google Scholar
- 69 : Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence. J Urol2003; 169: 124. abstract 481. Google Scholar
- 70 : Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol2003; 169: 351. abstract DP50. Google Scholar
- 71 : Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rates. J Physiol1967; 188: 1. Google Scholar
- 72 : Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol1980; 312: 255. Google Scholar
- 73 : Phosphorylation of 25-kDa Synaptosome-associated protein. Possible involvement in protein kinase C-mediated regulation of neurotransmitter disease. J Biol Chem1996; 271: 14548. Google Scholar
- 74 : Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release. Eur J Pharmacol1989; 164: 45. Google Scholar
- 75 : Frequency dependence of muscarinic facilitation of transmitter release in urinary bladder strips from neurally intact or chronic spinal cord transected rats. Br J Pharmacol1998; 125: 241. Crossref, Medline, Google Scholar
- 76 : Pharmacology and immunology of botulinum toxin serotypes. J Neurol2001; 248: 3. Google Scholar
- 77 : Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull2003; 61: 165. Google Scholar
- 78 : Double-blind study of botulinum toxin in spasmodic torticollis. Lancet1986; 2: 245. Google Scholar
- 79 : Botulinum toxin in the treatment of myofascial pain syndrome. Pain1994; 59: 65. Crossref, Medline, Google Scholar
- 80 : Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache2000; 40: 445. Google Scholar
- 81 : Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon2000; 38: 245. Google Scholar
- 82 : A method for the measurement of [3H]-glutamate release from cultured dorsal root ganglion neurons. Biochem Soc Trans1998; 26: S108. Google Scholar
- 83 : Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia2000; 20: 414. Google Scholar
- 84 : Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions. J Urol2002; 167: 41. abstract 164. Google Scholar
- 85 : Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol Res2003; 30: 399. Google Scholar
- 86 : Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet1998; 352: 625. Google Scholar
- 87 : Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci2002; 205: 59. Google Scholar
- 88 : Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol2003; 250: 188. Google Scholar
- 89 : Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology2003; 62: 259. Google Scholar
From the Scott Department of Urology, Baylor College of Medicine, Houston, Texas (CPS), and Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania (MBC)
© 2004 by American Urological Association, Inc.
